SANTA CRUZ BIOTECHNOLOGY, INC.

BRI3BP (h): 293T Lysate: sc-113862

BACKGROUND

BRI3BP (BRI3 binding protein), also known as BNAS1, HCCR-1, I3-binding protein or cervical cancer 1 proto-oncogene-binding protein KG19, is a 251 amino acid multi-pass membrane protein. Though widely expressed, BRI3BP is found at highest levels in brain, kidney and liver where it localizes to the endoplasmic reticulum (ER) and is involved in ER structural dynamics and mitochondrial viability. Possessing pro-apoptotic properties and the ability to potentiate drug-induced apoptosis, BRI3BP overexpression has been shown to enhance caspase-3 and mitochondrial cytochrome c release in etoposide-treated human embryonic kidney 293T cells. The gene encoding BRI3BP maps to human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.

REFERENCES

1. Delgado Carrasco, J., Casanova Morcillo, A., Zabalza Alvillos, M. and Ayala Garces, A. 2001. Achondrogenesis type II-hypochondrogenesis: radiological features. Case report. An. Esp. Pediatr. 55: 553-557.
2. Lin, L., Wu, Y., Li, C. and Zhao, S. 2001. Cloning, tissue expression pattern, and chromosome location of a novel human gene BRI3BP. Biochem. Genet. 39: 369-377.
3. Yokoyama, T., Nakatani, S. and Murakami, A. 2003. A case of Kniest dysplasia with retinal detachment and the mutation analysis. Am. J. Ophthalmol. 136: 1186-1188.
4. Forzano, F., Lituania, M., Viassolo, A., Superti-Furga, V., Wildhardt, G., Zabel, B. and Faravelli, F. 2007. A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and "patchy" expression in the mosaic father. Am. J. Med. Genet. A 143A: 2815-2820.
5. Yamazaki, T., Sasaki, N., Nishi, M., Yamazaki, D., Ikeda, A., Okuno, Y., Komazaki, S. and Takeshima, H. 2007. Augmentation of drug-induced cell death by ER protein BRI3BP. Biochem. Biophys. Res. Commun. 362: 971-975.
6. Wainwright, H. and Beighton, P. 2008. Visceral manifestations of hypochondrogenesis. Virchows Arch. 453: 203-207.
7. Lo, F.S., Luo, J.D., Lee, Y.J., Shu, S.G., Kuo, M.T. and Chiou, C.C. 2009. High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome. Clin. Chim. Acta 409: 75-77.
8. Benussi, D.G., Costa, P., Zollino, M., Murdolo, M., Petix, V., Carrozzi, M. and Pecile, V. 2009. Trisomy 12p and monosomy 4p: phenotype-genotype correlation. Genet. Test. Mol. Biomarkers 13: 199-204.

CHROMOSOMAL LOCATION

Genetic locus: BRI3BP (human) mapping to 12q24.31.

PRODUCT

BRI3BP (h): 293T Lysate represents a lysate of human BRI3BP transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

BRI3BP (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive BRI3BP antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.